impaired fat oxidation impaired lipid catabolism
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: * Male sex * Age 45-65 years * Body fat percentage > 25, BMI 30-35 kg/m2 * Sedentary * Stable dietary habits * Willingness to abstain from ingestion of resveratrol-containing foods * Healthy
Exclusion criteria
Exclusion criteria: * Female sex * Unstable body weight (weight gain or loss > 3 kg in the last three months) * Total body fat (%) 6.1 mmol/l HB 2 hours total per week * Impaired kidney and/ or hepatic function * First- or second-degree family member with type 2 diabetes mellitus * Any medical condition requiring treatment and/or medication use * Intake of dietary supplements except vitamins and minerals * Unwilling to restrict high-resveratrol-containing foods * Current alcohol consumption > 20 grams/day * Participation in another biomedical study within 1 month before the first screening visit * A contraindication to MRI scanning. These contra-indications include patients with the following devices: o Central nervous system aneurysm clips o Implanted neural stimulator o Implanted cardiac pacemaker of defibrillator o Cochlear implant o Insulin pump o metal containing corpora aliena in the eye or brains
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome parameter is the difference in mitochondrial number, intrinsic function and fat oxidative capacity after a 4 week treatment with ResvidaTM compared to the placebo trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the differences in skeletal muscle and liver lipid content, and lipolysis in skeletal muscle and adipose tissue after 4 weeks ResvidaTM or placebo supplementation. | — |
Countries
Netherlands